

TRIAL/PROGRAM STATUS - 1st SEPTEMBER 2021

[First Patient Randomized in Ph 2 Trial of Tedopi® in Combination with Pembrolizumab in Ovarian Cancer](#)

Dr Alexandra Leary, Chief Investigator of TEDOVA study from Gustave Roussy cancer center, comments: “We are very pleased to announce enrolment of the first patient in TEDOVA, the first trial evaluating an innovative maintenance strategy for patients in first or second platinum sensitive relapse post-PARP inhibitor and bevacizumab. We look forward to evaluating this therapeutic option for women with ovarian cancer and a strong unmet medical need”.

[First Patient Dosed in Ph 1/2 Study of RVU120 \(SEL120\) in Patients with R/R Metastatic or Advanced Solid Tumors and CMO Transition](#)

“CDK8 represents an important potential therapeutic target in various types of cancer, and RVU120, an orally available small molecule, is potentially both the first and best in class CDK8 inhibitor. We are delighted to have a new Phase I/II RVU120 study in patients with solid tumors conducted in Poland, and we are planning on further expansion of clinical sites in other European countries,” comments Pawel Przewiezlikowski, Chief Executive Officer at Ryvu Therapeutics.

[First Patient Treated In CAPAFOUR Study Investigating Combination Of Nadunolimab With FOLFIRINOX In Pancreatic Cancer](#)

“As Cantargia’s vision is to provide cancer patients with novel treatments, the start of this trial is a moment of pride. Based on the synergies observed between CAN04 and platinum-based chemotherapy, we have high expectations on the outcome of this study.”, said Göran Forsberg, CEO of Cantargia.

[First Patient Treated in Ph 2a Trial of Infigratinib in Patients with Gastric Cancer and Other Advanced Solid Tumors](#)

“Infigratinib is a potent and selective FGFR inhibitor that has demonstrated compelling clinical activity across multiple tumor types with FGFR alterations,” said Yizhe Wang, Ph.D., chief executive officer of LianBio. “Given the disproportionately high prevalence rate of gastric cancer in China, LianBio is pursuing a region-specific development strategy focused on this area of great unmet need. This study marks LianBio’s first trial initiation and demonstrates our continued progress in delivering potentially transformational medicines to patients in Asia.”

[Ph 1b Trial completed and Ph 2 initiated for CPI-613® \(devimistat\) + Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer](#)

“We are extremely excited and gratified to have completed Phase 1b and to be able to advance to the next phase (Phase 2),” said Sanjeev Luther, President and CEO of Rafael Pharmaceuticals. “Advanced biliary tract cancer is a rare and aggressive cancer with a 5-year survival rate of less than 5%, and the continuation of the trial aligns with our mission to help patients with significant unmet medical needs.”

[Ph 2 Study of Bintrafusp Alfa in 1L Biliary Tract Cancer patients to be discontinued](#)

Ph 2 INTR@PID BTC 055 study evaluating bintrafusp alfa with gemcitabine plus cisplatin in the first-line treatment of patients with locally advanced or metastatic biliary tract cancer (BTC) to be discontinued as the study is unlikely to achieve the primary objective of overall survival. No new safety signals were identified.